title: Vaccination with inactivated or live-attenuated chimeric PCV1-2 results in decreased viremia in challenge-exposed pigs and may reduce transmission of PCV2.
abstract: The objectives were to determine transmissibility of PCV2 to naïve contact pigs 140 days after infection of resident pigs and the benefit of vaccination with live-attenuated or inactivated chimeric PCV2 vaccines on chronic PCV2 infection. Twelve 6-week old PCV2 naïve pigs were randomly divided into four groups of three pigs: negative controls, positive controls, and pigs vaccinated with either a live-attenuated or inactivated chimeric PCV1-2 vaccine. All animals were bled weekly and tested for anti-PCV2 antibodies and PCV2 and PCV1-2 DNA and all groups except negative controls were challenged at 10 weeks. Two pigs vaccinated with the live PCV2 vaccine were PCV1-2 viremic at a single observation point. Both vaccine regimens induced an anti-PCV2 antibody response which was detected sooner and reached a higher level with the commercial inactivated vaccine. Both vaccines significantly decreased the concentration and duration of PCV2 viremia compared to the positive controls. PCV2 DNA was detected in lymphoid tissues of 1/3 pigs in the live-attenuated vaccine group and 3/3 positive control pigs. Three, 2-week old, PCV2 naïve contact pigs were comingled with each group at 168 days post-vaccination or 140 days post-challenge. After seven days of co-housing, the resident pigs were removed and the contact pigs remained for six weeks. Evidence of chimeric PCV1-2 vaccine or PCV2 challenge virus transmission to naïve contact pigs was lacking in all groups. The results of this study suggest that 140-day closure of a small pig population in a controlled environment may result in stabilization and elimination of PCV2.
authors.affiliation: Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, 1600 S. 16th Street, Ames, IA 50011, USA.
authors.forename: M
authors.initials: M
authors.lastname: Hemann
authors.forename: N M
authors.initials: NM
authors.lastname: Beach
authors.forename: X J
authors.initials: XJ
authors.lastname: Meng
authors.forename: P G
authors.initials: PG
authors.lastname: Halbur
authors.forename: T
authors.initials: T
authors.lastname: Opriessnig
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000032:analysis; D018173:Circoviridae Infections / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D017925:Circovirus; D008221:Lymphoid Tissue / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D034421:Sus scrofa; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014765:Viral Vaccines